Novartis AG NOVN

SWX: NOVN | ISIN: CH0012005267 27/04/2026

114,08 CHF (+0,33%)

(+0,33%) 27/04/2026

Grafiek Novartis AG

Grafiek Novartis AG

1 dag1d 0,33%
1 week1w -1,74%
1 maand1m -4,79%
3 maanden3m -0,11%
6 maanden6m 15,38%
1 jaar1j 22,14%
5 jaar5j 44,19%

dinsdag 28 april 2026, 07:00

Kwartaalcijfers (1ste kwartaal)

Novartis AG in het nieuws

Toon enkel gratis nieuws

28 april 2026 · Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed · Persbericht

27 april 2026 · Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria · Persbericht

24 april 2026 · Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA) · Persbericht

24 april 2026 · Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants · Persbericht

9 april 2026 · Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030 · Persbericht

29 maart 2026 · Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% · Persbericht

27 maart 2026 · Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation · Persbericht

23 maart 2026 · Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 · Persbericht

20 maart 2026 · Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline · Persbericht

13 maart 2026 · Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa · Persbericht

Profiel Novartis AG

Gezondheidstechnologie

Medicinale en botanische productie

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe